1. Cancer immunotherapy
2. Clinical cancer research
3. Recombinant antibodies
4. Signalling inhibitors

The laboratory research has focused on the development and preclinical characterization of targeting strategies to tumours with recombinant antibodies and signalling inhibitors for diagnostic and therapeutic applications. Studies investigating the enhancement of antibody's immune effector function, the mechanisms of antibody-antigen binding and intracellular movement through cancer cells; and the generation of custom designed constructs through genetic engineering are being performed.

In addition, the laboratory supports the Program's clinical trials through the preparation of radiolabelled reagents for administration to trial patients and performing analyses of patient sera samples for pharmacokinetic and immunological response data. As part of the International Ludwig Institute Clinical Trials, Phase I trials in colon, breast, lung, melanoma and renal cell cancers examining the safety, biodistribution and pharmacokinetics of recombinant antibodies have been conducted.

1. SCOTT AM, Lee F-T, Hopkins W, Cebon JS, Wheatley JM, Liu Z, Smyth FE, Murone C, Sturrock S, MacGregor D, Hanai N, Inoue K, Yamasaki M, Brechbiel MW, Davis ID, Murphy R, Hannah A, Lim-Joon M, Chan T, Chong G, Ritter G, Hoffman EW, Burgess AW, Old LJ. Specific Targeting, Biodistribution and Lack of Immunogenicity of Chimeric Anti-GD3 Monoclonal Antibody KM871 in Patients With Metastatic Melanoma - Results of a Phase I Trial. J Clin Oncol 19(19): 3976-87, 2001.

2. Luwor R, Johns TG, Murone C, Su Huang H-J, Cavenee WK, Ritter G, Old LJ, Burgess AW, SCOTT AM. Monoclonal Antibody 806 Inhibits the Growth of Tumor Xenografts Expressing either the de2-7 or Amplified Epidermal Growth Factor Receptor (EGFR) but not wild type EGFR. Cancer Research 15: 5355-5361, 2001.

3. Tochon-Danguy HJ, Sachinidis JI, Chan F, Chan JG, Hall C, Cher L, Stylli S, Hill J, Kaye A, SCOTT AM. Imaging and Quantitation of the Hypoxic Cell Fraction of Viable Tumour in an Animal Model of Intracerebral High Grade Glioma using 18F-Fluoromisonidazole (FMISO). Nucl Med Biol 29(2):191-7, 2002.

4. Johns TG, Stockert E, Ritter G, Jungbluth AA, S. Huang H-J, Cavenee W, Hall C, Watson N, Nice EC, Old LJ, Burgess AW, SCOTT AM. A Novel Antibody Specific for the Delta2-7 Epidermal Growth Factor Receptor (EGFR) that Also Recognises the EGFR Expressed in Cells Containing Amplification of the EGFR Gene. Int J Cancer 98:398-408, 2002.

5. Liu, Z, Smyth, FE, Renner, C, Lee, F-T, Oosterwijk, E, and SCOTT, AM. Anti-Renal Cell Carcinoma Chimeric Antibody G250: Cytokine Enhancement Of In Vitro Antibody-Dependent Cellular Cytotoxicity. Cancer Immunol Immunother., 51: 171-177, 2002.

6. SCOTT AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W, Divgi CR, Hanson LH, Mitchell P, Gansen DN, Larson SM, Ingle JN, Hoffman EW, Tanswell P, Ritter G, Cohen LS, Bette P, Arvay L, Amelsberg A, Vlock D, Rettig WJ, Old LJ. A Phase I Dose-Escalation Study of Sibrotuzumab in Patients with Advanced or Metastatic Fibroblast Activation Protein-positive Cancer. Clin Cancer Res. 2003 9:1639-47.

7. Tahtis K, Lee FT, Wheatley JM, Garin-Chesa P, Park JE, Smyth FE, Obata Y, Stockert E, Hall CM, Old LJ, Rettig WJ, SCOTT AM. Expression and targeting of human fibroblast activation protein in a human skin/severe combined immunodeficient mouse breast cancer xenograft model. Mol Cancer Ther. 2003 2:729-37.